公开(公告)号：US10968231B2

公开(公告)日：2021-04-06

申请号：US16497141

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  SCOHIA PHARMA, INC

Inventor： Seiji Miwatashi ,  Yasufumi Miyamoto ,  Koji Watanabe ,  Yayoi Nakayama ,  Yuko Hitomi ,  Jumpei Aida ,  Nobuyuki Takakura ,  Hideki Furukawa ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Shizuo Kasai ,  Toshitake Kobayashi ,  Tsuyoshi Maekawa ,  Satoshi Sasaki ,  Shigemitsu Matsumoto

IPC: C07D491/052 ,  C07D211/22 ,  C07D401/12 ,  C07D401/14

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US12202832B2

公开(公告)日：2025-01-21

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji Kitamura ,  Zenichi Ikeda ,  Minoru Ikoma ,  Koji Watanabe ,  Hideki Hirose ,  Takafumi Yukawa ,  Sachie Morimoto ,  Naoki Nishizawa ,  Taiji Asami

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  A61K31/4184 ,  A61K47/38 ,  A61P9/04

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US10919891B2

公开(公告)日：2021-02-16

申请号：US16608140

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji Kitamura ,  Zenichi Ikeda ,  Sachie Morimoto ,  Minoru Ikoma ,  Koji Watanabe ,  Hideki Hirose ,  Takafumi Yukawa ,  Kenjiro Sato

IPC: C07D471/04 ,  A61P9/06 ,  A61P9/12

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US11186565B2

公开(公告)日：2021-11-30

申请号：US16499432

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji Miwatashi ,  Yasufumi Miyamoto ,  Koji Watanabe ,  Yayoi Nakayama ,  Yuko Hitomi ,  Jumpei Aida ,  Nobuyuki Takakura ,  Hideki Furukawa ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Kazuaki Takami ,  Norihito Tokunaga ,  Tomohiro Okawa ,  Akito Shibuya ,  Shizuo Kasai ,  Toshitake Kobayashi ,  Tsuyoshi Maekawa

IPC: C07D401/12 ,  C07C59/72 ,  C07D211/22 ,  C07D213/64 ,  C07D401/10 ,  C07D401/14 ,  C07D413/10

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US09776962B2

公开(公告)日：2017-10-03

申请号：US14898633

申请日：2014-08-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Jumpei Aida ,  Yayoi Yoshitomi ,  Yuko Hitomi ,  Naoyoshi Noguchi ,  Yasuhiro Hirata ,  Hideki Furukawa ,  Akito Shibuya ,  Koji Watanabe ,  Yasufumi Miyamoto ,  Tomohiro Okawa ,  Nobuyuki Takakura ,  Seiji Miwatashi

IPC: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.